Soumyajit Roy, MD, of Rush University Medical Center, and Christopher Wallis, MD, PhD, FRCSC, of University of Toronto, break down the latest secondary analysis of the SPARTAN trial.
In this trial, researchers assessed the effects of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.